Literature DB >> 27630251

Candida species diversity and antifungal susceptibility patterns in oral samples of HIV/AIDS patients in Baja California, Mexico.

Isadora Clark-Ordóñez1,2, Olga A Callejas-Negrete1, Elva T Aréchiga-Carvajal3, Rosa R Mouriño-Pérez1.   

Abstract

Candidiasis is the most common opportunistic fungal infection in HIV patients. The aims of this study were to identify the prevalence of carriers of Candida, Candida species diversity, and in vitro susceptibility to antifungal drugs. In 297 HIV/AIDS patients in Baja California, Mexico, Candida strains were identified by molecular methods (PCR-RFLP) from isolates of oral rinses of patients in Tijuana, Mexicali, and Ensenada. 56.3% of patients were colonized or infected with Candida. In Tijuana, there was a significantly higher percentage of carriers (75.5%). Out of the 181 strains that were isolated, 71.8% were Candida albicans and 28.2% were non-albicans species. The most common non-albicans species was Candida tropicalis (12.2%), followed by Candida glabrata (8.3%), Candida parapsilosis (2.2%), Candida krusei (1.7%), and Candida guilliermondii (1.1%). Candida dubliniensis was not isolated. Two associated species were found in 11 patients. In Mexicali and Ensenada, there was a lower proportion of Candida carriers compared to other regions in Mexico and worldwide, however, in Tijuana, a border town with many peculiarities, a higher carrier rate was found. In this population, only a high viral load was associated with oral Candida carriers. Other factors such as gender, use of antiretroviral therapy, CD4+ T-lymphocyte levels, time since diagnosis, and alcohol/ tobacco consumption, were not associated with Candida carriers.
© The Author 2016. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  AIDS; Candida; HIV; Mexico; antifungal drug resistance; molecular epidemiology; oral candidiasis

Mesh:

Substances:

Year:  2017        PMID: 27630251     DOI: 10.1093/mmy/myw069

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   4.076


  5 in total

1.  Candida spp. Determination and Th1/Th2 Mixed Cytokine Profile in Oral Samples From HIV+ Patients With Chronic Periodontitis.

Authors:  Sarah M Lomeli-Martinez; Eulogio Valentin-Goméz; Juan J Varela-Hernández; Monserrat Alvarez-Zavala; Karina Sanchez-Reyes; Moises Ramos-Solano; Rodolfo I Cabrera-Silva; Victor M Ramirez-Anguiano; Manuel A Lomeli-Martinez; Silvia Y Martinez-Salazar; Luz A González-Hernández; Jaime F Andrade-Villanueva
Journal:  Front Immunol       Date:  2019-06-27       Impact factor: 7.561

2.  Association of oral candidal species with human immunodeficiency virus patients of West Godavari district, Andhra Pradesh - An in vitro study.

Authors:  R Mounika; Govindraj K Nalabolu; N Pallavi; Smita S Birajdar
Journal:  J Oral Maxillofac Pathol       Date:  2021-05-14

3.  The prevalence, risk factors and antifungal sensitivity pattern of oral candidiasis in HIV/AIDS patients in Kumba District Hospital, South West Region, Cameroon.

Authors:  Ngwa Fabrice Ambe; Njunda Anna Longdoh; Patience Tebid; Tanyi Pride Bobga; Claude Ngwayu Nkfusai; Sangwe Bertrand Ngwa; Frankline Sanyuy Nsai; Samuel Nambile Cumber
Journal:  Pan Afr Med J       Date:  2020-05-19

4.  Genetic diversity and antifungal susceptibility of Candida albicans isolates from Iranian HIV-infected patients with oral candidiasis.

Authors:  Iradj Ashrafi Tamai; Babak Pakbin; Bahar Nayeri Fasaei
Journal:  BMC Res Notes       Date:  2021-03-10

Review 5.  Antifungal Resistance in Clinical Isolates of Candida glabrata in Ibero-America.

Authors:  Erick Martínez-Herrera; María Guadalupe Frías-De-León; Rigoberto Hernández-Castro; Eduardo García-Salazar; Roberto Arenas; Esther Ocharan-Hernández; Carmen Rodríguez-Cerdeira
Journal:  J Fungi (Basel)       Date:  2021-12-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.